Allos Therapeutics Inc. (ALTH)

[mlkrborn]

Allos Therapeutics initiates Phase 3 registration trial of FOLOTYN in newly diagnosed patients with peripheral T-Cell Lymphoma following treatment with a CHOP-based regimen (ALTH) 1.74 : Co announced the enrollment of the first patient in a Phase 3 randomized clinical trial evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma. This study is open to enroll newly diagnosed patients with PTCL who have achieved an objective response following initial treatment with CHOP or a CHOP-like regimen. Earlier this year, Allos reached agreement with the FDA under its Special Protocol Assessment process on the design of this Phase 3 trial.